Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
Global Postoperative Nausea and Vomiting (PONV) market size was valued at USD 1,958 million in 2024. The market is projected to grow from USD 2,096 million in 2025 to USD 3,117 million by 2031, exhibiting a CAGR of 7.0% during the forecast period.
Postoperative nausea and vomiting (PONV) refers to nausea and vomiting that occurs after anesthesia and surgical procedures. It is one of the most common complications following surgery, affecting approximately 30% of all surgical patients and up to 80% of high-risk patients. The condition can lead to serious complications like dehydration, electrolyte imbalance, and wound dehiscence if not managed properly.
The market growth is driven by increasing surgical volumes worldwide and growing awareness about PONV management. However, the market faces challenges including stringent regulatory requirements for new drug approvals and pricing pressures. North America currently dominates the market due to high healthcare expenditure and advanced surgical infrastructure, while Asia-Pacific is expected to show the highest growth due to improving healthcare facilities and rising surgical procedures.
Increasing Surgical Procedures Worldwide
The global PONV market is driven by the rising number of surgical procedures, exceeding 300 million annually. As surgical volumes grow, particularly in developing nations, the demand for effective PONV prevention and treatment increases proportionally.
Advancements in Antiemetic Therapies
Pharmaceutical innovations have led to more effective combination therapies and long-acting formulations, with the antiemetic drug market expected to grow at 6.2% CAGR through 2028. New 5-HT3 receptor antagonists and NK-1 receptor antagonists show improved efficacy profiles.
Recent studies show multimodal approaches combining dexamethasone with 5-HT3 antagonists reduce PONV incidence by up to 80% in high-risk patients
Growing awareness among anesthesiologists about risk stratification protocols is driving adoption of targeted prophylaxis, supported by professional guidelines from organizations like ASRA and APSF.
MARKET CHALLENGES
High Cost of Novel Therapies
The premium pricing of newer antiemetic drugs, particularly patent-protected formulations, creates cost barriers for widespread adoption in price-sensitive healthcare systems.
Other Challenges
Underreporting in Home Recovery
Approximately 35% of PONV cases occur post-discharge, making accurate incidence tracking and treatment difficult in outpatient settings.
Variable Risk Assessment Implementation
Despite established risk scoring systems like Apfel's, inconsistent application across institutions leads to suboptimal prophylaxis strategies.
Generic Competition
Patent expirations of key drugs like ondansetron have led to price erosion, with generic versions now accounting for over 70% of 5-HT3 antagonist prescriptions, impacting market growth for branded formulations.
Ambulatory Surgery Center Expansion
The shift toward outpatient procedures creates new demand for rapid-acting, short-duration antiemetics, with the ASC market projected to grow at 8.4% annually through 2030.
Personalized Medicine Approaches
Emerging pharmacogenomic testing for antiemetic drug metabolism presents opportunities for tailored therapies that could improve outcomes in resistant patient populations.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Serotonin Antagonists dominate the PONV treatment landscape due to their proven efficacy and widespread clinical acceptance. NK-1 Receptor Antagonists are gaining traction as second-line therapies, while non-pharmacologic treatments appeal to patients seeking alternative approaches with minimal side effects. |
| By Application |
|
Hospital Pharmacies represent the primary distribution channel for PONV medications, driven by immediate post-operative administration needs. Online pharmacies demonstrate strong growth potential with increasing prescription digitization, while retail pharmacies serve as important access points for outpatient follow-up treatments. |
| By End User |
|
Hospitals account for the majority of PONV treatment demand due to their high surgical volumes and critical care capabilities. Ambulatory surgical centers show increasing adoption of PONV protocols as outpatient procedures become more complex. Specialty clinics focusing on surgical recovery demonstrate targeted use of advanced PONV therapies. |
| By Therapy Approach |
|
Combination Therapy is emerging as the most effective strategy for high-risk patients, integrating multiple drug classes for comprehensive symptom control. Prophylactic treatment remains standard for most surgical cases, while therapeutic approaches are reserved for breakthrough PONV incidents requiring immediate intervention. |
| By Risk Profile |
|
High-Risk Patients drive innovation in PONV management, requiring personalized treatment regimens and close monitoring. Moderate-risk patients benefit most from standardized protocols, while low-risk cases demonstrate high satisfaction with basic preventative measures. Risk stratification continues to guide clinical decision-making in PONV management. |
Global PONV Market Dominated by Pharmaceutical Giants and Specialized Players
The PONV market is characterized by a mix of large pharmaceutical conglomerates and specialized biopharma companies, with Merck & Co. and GlaxoSmithKline leading through their comprehensive antiemetic portfolios. These industry leaders maintain dominance through extensive R&D investments and established distribution networks in hospital pharmacy channels. The market structure remains moderately concentrated, with top 5 players collectively holding approximately 45% revenue share in 2024.
Emerging players like Acacia Pharma and Helsinn Holding are gaining traction through targeted therapies and novel drug delivery systems. Niche participants such as Camurus focus on innovative NK-1 receptor antagonists, while regional specialists like Eisai maintain strong positions in Asia-Pacific markets. Several mid-sized players are actively pursuing combination therapies to address the growing demand for multimodal PONV prevention approaches.
List of Key Postoperative Nausea and Vomiting (PONV) Companies ProfiledEisai Co., Ltd.
Camurus AB
Heron Therapeutics, Inc.
Pfizer Inc.
Baxter International Inc.
Teva Pharmaceutical Industries Ltd.
Mylan N.V.
The global PONV market was valued at $1958 million in 2024 and is projected to reach $3117 million by 2031, growing at a CAGR of 7.0%. This growth is driven by increasing surgical procedures worldwide and higher postoperative complication rates. The market expansion reflects the critical need for effective nausea and vomiting management following anesthesia and surgery.
Other TrendsDrug Class Segmentation
Serotonin antagonists dominate the PONV treatment market with over 35% share, followed closely by NK-1 receptor antagonists which are gaining adoption. Combination therapies incorporating multiple drug classes are becoming standard practice, with research showing they reduce PONV incidence by up to 80% compared to single-agent approaches.
Regional Market VariationsNorth America currently leads the PONV market with 42% global share, attributed to advanced healthcare infrastructure and high surgical volumes. Asia-Pacific is projected as the fastest growing region at 9.2% CAGR through 2031, driven by expanding medical tourism and improving hospital facilities in India, China, and Southeast Asia.
Distribution Channel Growth
Hospital pharmacies account for 58% of PONV drug distribution, reflecting immediate postoperative treatment needs. Online pharmacies are experiencing the fastest growth at 11% annually, supported by increasing digital health adoption and prescription fulfillment services.
Innovation and Pipeline DevelopmentsMajor pharmaceutical companies are investing in next-generation PONV treatments, with 12 novel compounds in clinical trials as of 2024. Transdermal patches and extended-release formulations show particular promise for improving patient compliance and reducing nursing workload in postoperative care settings.
Regional Analysis: Postoperative Nausea and Vomiting (PONV) MarketEurope
Europe shows strong PONV management standards, with notable variations between Western and Eastern regions. The EU's centralized approval process facilitates antiemetic availability, while national guidelines emphasize cost-effectiveness. Germany and Nordic countries lead in protocol adherence, with anesthesia teams routinely using risk-adapted strategies. The market faces pricing pressures but maintains innovation through hospital-pharma collaborations on specialized formulations. Eastern Europe demonstrates growing awareness, though resource limitations sometimes restrict optimal prophylaxis.
Asia-Pacific
The Asia-Pacific region represents the fastest-growing PONV market, driven by expanding surgical volumes and improving healthcare access. Japan maintains sophisticated practice standards with early adoption of newer antiemetics, while China shows rapidly increasing demand. Market growth faces challenges including inconsistent risk assessment implementation and variable access to newer medications across different care settings. Cultural factors influence patient expectations around nausea management, particularly in private hospitals competing on patient experience metrics.
South America
In South America, urbanization and increasing elective surgeries drive PONV market expansion. Brazil leads in clinical guideline adoption, though economic volatility affects medication availability. Public hospitals often rely on first-generation antiemetics, while private centers increasingly use combination therapies. Regional medical societies actively promote PONV prevention education but face infrastructure limitations in remote areas. Market potential remains strong, particularly for cost-effective generic options.
Middle East & Africa
The Middle East shows growing PONV market sophistication, especially in GCC countries investing heavily in healthcare modernization. Premium hospitals emulate Western protocols, while broader markets remain price-sensitive. Africa presents the most variability, with urban reference centers demonstrating advanced practice but limited rural access to basic antiemetics. The region shows untapped potential as surgical capacities expand, though economic and infrastructure challenges persist.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252031. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Healthcare providers and hospital systems
Medical device manufacturers
Contract research organizations
Investors, consultants, and policy makers
-> Global Postoperative Nausea and Vomiting (PONV) market was valued at USD 1,958 million in 2024 and is expected to reach USD 3,117 million by 2031.
Which key companies operate in Global PONV Market?
-> Key players include Acacia Pharma, F. Hoffmann-La Roche, Novartis, Ani Pharmaceuticals, Camurus, and Sanofi, among others.
-> The market is projected to grow at a CAGR of 7.0% during 2025-2031.
-> North America currently dominates the market, while Asia-Pacific is expected to show the highest growth.
-> Key drivers include increasing surgical volumes worldwide and growing awareness about PONV management.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates